SE0002934D0 - New aporphine esters and in their use in therapy - Google Patents

New aporphine esters and in their use in therapy

Info

Publication number
SE0002934D0
SE0002934D0 SE0002934A SE0002934A SE0002934D0 SE 0002934 D0 SE0002934 D0 SE 0002934D0 SE 0002934 A SE0002934 A SE 0002934A SE 0002934 A SE0002934 A SE 0002934A SE 0002934 D0 SE0002934 D0 SE 0002934D0
Authority
SE
Sweden
Prior art keywords
therapy
parkinson
disease
disclosed
new
Prior art date
Application number
SE0002934A
Other languages
English (en)
Swedish (sv)
Inventor
Haakan Vilhelm Wikstroem
Durk Dijkstra
Thomas Ivo Franchiscus Cremers
Per Erik Andren
Marchais Sandrine
Ulrik Jurva
Original Assignee
Axon Biochemicals Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axon Biochemicals Bv filed Critical Axon Biochemicals Bv
Priority to SE0002934A priority Critical patent/SE0002934D0/xx
Publication of SE0002934D0 publication Critical patent/SE0002934D0/xx
Priority to CA2419842A priority patent/CA2419842C/en
Priority to MXPA03001465A priority patent/MXPA03001465A/es
Priority to PL36008901A priority patent/PL360089A1/xx
Priority to AU7122801A priority patent/AU7122801A/xx
Priority to JP2002519422A priority patent/JP2004506041A/ja
Priority to HU0301685A priority patent/HUP0301685A3/hu
Priority to US10/344,420 priority patent/US7238705B2/en
Priority to CZ2003454A priority patent/CZ2003454A3/cs
Priority to EA200300266A priority patent/EA006388B1/ru
Priority to CNB018142222A priority patent/CN1242991C/zh
Priority to EP01950203A priority patent/EP1309553A1/en
Priority to BR0113291-1A priority patent/BR0113291A/pt
Priority to NZ523893A priority patent/NZ523893A/en
Priority to PCT/SE2001/001658 priority patent/WO2002014279A1/en
Priority to IL15409601A priority patent/IL154096A0/xx
Priority to KR1020037002274A priority patent/KR100865503B1/ko
Priority to AU2001271228A priority patent/AU2001271228B2/en
Priority to IL154096A priority patent/IL154096A/en
Priority to ZA200300828A priority patent/ZA200300828B/en
Priority to NO20030677A priority patent/NO324409B1/no
Priority to US11/061,881 priority patent/US7332503B2/en
Priority to US12/021,560 priority patent/US20080119504A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
SE0002934A 2000-08-17 2000-08-17 New aporphine esters and in their use in therapy SE0002934D0 (sv)

Priority Applications (23)

Application Number Priority Date Filing Date Title
SE0002934A SE0002934D0 (sv) 2000-08-17 2000-08-17 New aporphine esters and in their use in therapy
AU2001271228A AU2001271228B2 (en) 2000-08-17 2001-07-20 New aporphine esters and their use in therapy
CNB018142222A CN1242991C (zh) 2000-08-17 2001-07-20 阿朴啡酯类及其治疗用途
BR0113291-1A BR0113291A (pt) 2000-08-17 2001-07-20 steres de aporfina e seu uso em terapia
PL36008901A PL360089A1 (en) 2000-08-17 2001-07-20 New aporphine esters and their use in therapy
AU7122801A AU7122801A (en) 2000-08-17 2001-07-20 New aporphine esters and their use in therapy
JP2002519422A JP2004506041A (ja) 2000-08-17 2001-07-20 新規アポルフィンエステルおよび治療におけるそれらの使用
HU0301685A HUP0301685A3 (en) 2000-08-17 2001-07-20 New aporphine esters and their use in therapy, process for their preparation and pharmaceutical compositions containing them
US10/344,420 US7238705B2 (en) 2000-08-17 2001-07-20 Aporphine esters and their use in therapy
CZ2003454A CZ2003454A3 (cs) 2000-08-17 2001-07-20 Nové estery aporfinu a jejich využití v terapii
EA200300266A EA006388B1 (ru) 2000-08-17 2001-07-20 Сложные эфиры апорфина и их применение в терапии
CA2419842A CA2419842C (en) 2000-08-17 2001-07-20 New aporphine esters and their use in therapy
EP01950203A EP1309553A1 (en) 2000-08-17 2001-07-20 New aporphine esters and their use in therapy
MXPA03001465A MXPA03001465A (es) 2000-08-17 2001-07-20 Nuevos esteres de aporfina y su uso en terapia.
NZ523893A NZ523893A (en) 2000-08-17 2001-07-20 New aporphine esters and their use in therapy
PCT/SE2001/001658 WO2002014279A1 (en) 2000-08-17 2001-07-20 New aporphine esters and their use in therapy
IL15409601A IL154096A0 (en) 2000-08-17 2001-07-20 Aporphine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
KR1020037002274A KR100865503B1 (ko) 2000-08-17 2001-07-20 신규한 아포르핀 에스테르 및 치료 요법에서의 그 용도
IL154096A IL154096A (en) 2000-08-17 2003-01-23 History of aporphine, processes for their preparation and pharmaceutical preparations containing them
ZA200300828A ZA200300828B (en) 2000-08-17 2003-01-30 New aporphine esters and their use in therapy.
NO20030677A NO324409B1 (no) 2000-08-17 2003-02-11 Nye aporfinderivater, fremgangsmate for fremstilling derav, anvendelse derav samt farmasoytiske preparater omfattende derivatene
US11/061,881 US7332503B2 (en) 2000-08-17 2005-02-22 Aporphine esters and their use in therapy
US12/021,560 US20080119504A1 (en) 2000-08-17 2008-01-29 New aporphine esters and their use in therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0002934A SE0002934D0 (sv) 2000-08-17 2000-08-17 New aporphine esters and in their use in therapy

Publications (1)

Publication Number Publication Date
SE0002934D0 true SE0002934D0 (sv) 2000-08-17

Family

ID=20280719

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0002934A SE0002934D0 (sv) 2000-08-17 2000-08-17 New aporphine esters and in their use in therapy

Country Status (19)

Country Link
US (3) US7238705B2 (cs)
EP (1) EP1309553A1 (cs)
JP (1) JP2004506041A (cs)
KR (1) KR100865503B1 (cs)
CN (1) CN1242991C (cs)
AU (2) AU2001271228B2 (cs)
BR (1) BR0113291A (cs)
CA (1) CA2419842C (cs)
CZ (1) CZ2003454A3 (cs)
EA (1) EA006388B1 (cs)
HU (1) HUP0301685A3 (cs)
IL (2) IL154096A0 (cs)
MX (1) MXPA03001465A (cs)
NO (1) NO324409B1 (cs)
NZ (1) NZ523893A (cs)
PL (1) PL360089A1 (cs)
SE (1) SE0002934D0 (cs)
WO (1) WO2002014279A1 (cs)
ZA (1) ZA200300828B (cs)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002934D0 (sv) * 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
SE0102036D0 (sv) * 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
WO2004110449A1 (fr) * 2003-06-19 2004-12-23 Lotus Pharmaceutical Co., Ltd. Aporphine et oxoaporphine et leur utilisation a des fins medicales
WO2004112723A2 (en) 2003-06-20 2004-12-29 Ronald Aung-Din Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
US7648995B2 (en) 2004-04-13 2010-01-19 The Mclean Hospital Corporation R(—)-11-hydroxyaporphine derivatives and uses thereof
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
WO2009003147A1 (en) * 2007-06-26 2008-12-31 Parkinson's Institute Methods and compositions for the treatment of neurological disorders
US8431591B2 (en) 2007-07-12 2013-04-30 The Mclean Hospital Corporation R(−)-2-methoxy-11-hydroxyaporphine and derivatives thereof
US8129530B2 (en) 2007-08-31 2012-03-06 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
TWI404702B (zh) 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥
ES2315203B1 (es) * 2007-09-11 2010-01-13 Universidade De Santiago De Compostela Uso de oxoisoaporfinas y sus derivados como inhibidores selectivos de la monoamino oxidasa a.
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
CA2729346A1 (en) 2008-06-30 2010-01-14 Afgin Pharma, Llc Topical regional neuro-affective therapy
WO2010121159A1 (en) * 2009-04-17 2010-10-21 Somalabs, Inc. Method for the induction of a reward response by modulation of dopaminergic systems in the central nervous system
EA025054B1 (ru) 2009-06-12 2016-11-30 Сайнэпсус Терапьютикс, Инк. Единичная дозированная форма для сублингвального введения, включающая частицы апоморфина, для лечения болезни паркинсона или половой дисфункции
DK2651357T3 (da) 2010-12-16 2020-06-02 Sunovion Pharmaceuticals Inc Sublinguale film
WO2012109561A2 (en) * 2011-02-11 2012-08-16 The Regents Of The University Of Michigan Peptide compositions and methods for treating patients
WO2016172095A1 (en) 2015-04-21 2016-10-27 Cynapsus Therapeutics, Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
US10989704B2 (en) 2015-06-24 2021-04-27 Koninklijke Philips N.V. Sweat monitoring apparatus and monitoring method
CA3082757A1 (en) 2017-11-24 2019-05-31 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
CN111601587B (zh) * 2018-01-18 2024-03-05 勒科斯生物技术责任有限公司 阿扑吗啡·棕榈酸共晶固体颗粒晶型
CN112930180A (zh) * 2018-04-20 2021-06-08 通用医疗公司 用于跨血脑屏障递送的乙酰化前药
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US12384765B2 (en) 2019-05-21 2025-08-12 H. Lundbeck A/S Catecholamine prodrugs for use in the treatment of Parkinson's Disease
CN113677675B (zh) 2019-05-21 2024-07-26 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
CN113727712B (zh) 2019-05-21 2024-11-15 H.隆德贝克有限公司 用于治疗帕金森病的儿茶酚胺氨基甲酸酯前药
CN113727974B (zh) 2019-05-21 2025-01-07 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080456A (en) * 1971-10-26 1978-03-21 Schering Aktiengesellschaft Diacylapomorphines
AU3140577A (en) * 1976-12-13 1979-06-14 Sterling Drug Inc N-propylnorapormorphine diesters
DE2717001C2 (de) * 1977-04-18 1984-06-20 Karl O. Helm Ag, 2000 Hamburg Arzneimittel mit antithrombotischer Wirkung
DE3171561D1 (en) * 1980-05-08 1985-09-05 Univ Northeastern N-substituted aporphines, a method of inducing emesis and a method of controlling psychosis utilising the same
US4353912A (en) * 1980-05-08 1982-10-12 Northeastern University N-Haloalkyl nor apomorphines and method of inactivating dopamine receptor sites and enhancing dopaminergic activity therewith
WO1990012574A1 (en) * 1989-04-25 1990-11-01 Northeastern University Dopamine agonist compounds
GB9517062D0 (en) 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
GB9700878D0 (en) 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US6403605B1 (en) 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
IT1299566B1 (it) * 1998-07-17 2000-03-16 Ifi Istituto Farmacoterapico I Cerotto transdermico e composizioni farmaceutiche comprendenti r (-)- norapropilapomorfina cloridrato e/o s (+) - norapropilapomorfina
MXPA01011480A (es) * 1999-05-13 2002-06-04 Unihart Corp Composiciones farmaceuticas que comprenden apocodeina y/o sus derivados.
AU2001255818A1 (en) * 2000-04-07 2001-10-23 Tap Pharmaceutical Products Inc. Apomorphine derivatives and methods for their use
SE0002934D0 (sv) * 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
SE0102036D0 (sv) * 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
EP1950203A1 (en) 2007-01-24 2008-07-30 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds with ACAT, their preparation and use as medicaments

Also Published As

Publication number Publication date
HUP0301685A2 (hu) 2003-08-28
CZ2003454A3 (cs) 2003-06-18
NZ523893A (en) 2003-10-31
CN1447792A (zh) 2003-10-08
CN1242991C (zh) 2006-02-22
US7332503B2 (en) 2008-02-19
US20050143408A1 (en) 2005-06-30
IL154096A0 (en) 2003-07-31
IL154096A (en) 2009-11-18
KR100865503B1 (ko) 2008-10-28
US20040018956A1 (en) 2004-01-29
KR20030036703A (ko) 2003-05-09
NO324409B1 (no) 2007-10-08
MXPA03001465A (es) 2004-12-13
US20080119504A1 (en) 2008-05-22
AU2001271228B2 (en) 2006-02-02
NO20030677L (no) 2003-03-05
PL360089A1 (en) 2004-09-06
EA006388B1 (ru) 2005-12-29
AU7122801A (en) 2002-02-25
NO20030677D0 (no) 2003-02-11
BR0113291A (pt) 2004-01-06
CA2419842A1 (en) 2002-02-21
HUP0301685A3 (en) 2010-03-29
EA200300266A1 (ru) 2003-08-28
US7238705B2 (en) 2007-07-03
CA2419842C (en) 2011-10-18
JP2004506041A (ja) 2004-02-26
WO2002014279A1 (en) 2002-02-21
ZA200300828B (en) 2004-05-17
EP1309553A1 (en) 2003-05-14

Similar Documents

Publication Publication Date Title
SE0002934D0 (sv) New aporphine esters and in their use in therapy
ATE400573T1 (de) 1h-imidazochinolinderivate als proteinkinaseinhibitoren
IL173396A0 (en) Piperazine derivatives and their use as therapeutic agents
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
MY138352A (en) Benzothiazole derivatives
IL173032A0 (en) Pyridazine derivatives and their use as therapeutic agents
CY1108514T1 (el) Παραγωγα 1-φαινυλαλκανεκαρβοξυλικου οξεος για τη θεραπεια νευρογενων ασθενειων
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
BRPI0409611A (pt) derivados de piperazina e uso dos mesmos para o tratamento de doenças neurológicas e psiquiátricas
JO2371B1 (en) 4-phenyl-pyridine derivatives
SE0102036D0 (sv) Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
BG108207A (en) Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
ATE402176T1 (de) Pyrrolidin- und azetidinverbindungen alsccr5- antagonisten
WO2004108715A8 (en) 3-aryloxy and 3-heteroaryloxy substituted benzo(b) thiophenes as therapeutic agents with pi3k activity
TW200517107A (en) Novel formulation
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
YU4903A (sh) N-/5-///5-alkil-2-oksazolil/metil/tio/-2-tiazolil/ karboksamidni inhibitori ciklin zavisnih kinaza
DE602004007268D1 (de) CYCLOALKYLSULFANYL-SUBSTITUIERTE BENZOiBöTHIOPHENE ALS THERAPEUTISCHE MITTEL
MXPA05012953A (es) Benzo[b]tiofenos 3-arilsulfanil y 3-heteroarilsulfanil sustituidos como agentes terapeuticos.
CY1106409T1 (el) Παραγωγα κινολινης
ATE389655T1 (de) Pyrimidinderivate
PT1268472E (pt) Inibidores 3-aminopirazolicos de cinases dependentes da ciclina